Clinical trials: RA - Rheumatoid Arthritis
Rheumatoid Arthritis
Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis
The purpose of this pilot, exploratory study is to evaluate the safety, tolerance, pharmacokinetics and potential anti-inflammatory activity of an investigational agent, HE3286, when administered orally for 29 days to patients…
- Trial name
- NCT00712114
- Testing
- HE3286
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Harbor Therapeutics
Rheumatoid Arthritis
Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently…
- Trial name
- NCT02784106
- Testing
- M2951
- Where
- 2 sites in United States, Germany
- Volunteers
- 65 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Rheumatoid Arthritis
A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.
Imatinib is a member of a new class of drugs known as signal transduction inhibitors. The purpose of this study is to evaluate the efficacy, safety and tolerability of imatinib in the treatment of rheumatoid arthritis in…
- Trial name
- NCT00154336
- Testing
- Imatinib, Methotrexate
- Where
- 15 sites in Austria, Canada and 2 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis
This is a multicenter, randomized, double-blind phase2 study to evaluate the safety and investigate the efficacy of YRA-1909 in Patients with Rheumatoid Arthritis who are on a stable dose of Methotrexate(MTX) and who have an…
- Trial name
- NCT03275025
- Testing
- YRA-1909 low dose, YRA-1909 mid dose, YRA-1909 high dose
- Where
- 14 sites in South Korea
- Volunteers
- 116 people
- Sponsor
- Yungjin Pharm. Co., Ltd.
NSAID-induced Gastroduodenal Injury, Ulcers
Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
The primary purpose of this study is to determine the efficacy and safety of three dose levels of cobiprostone as compared to placebo in OA/RA patients treated with an NSAID for 20 months.
- Conditions
- NSAID-induced Gastroduodenal Injury, Ulcers, Rheumatoid Arthritis, Osteoarthritis
- Trial name
- NCT00597818
- Testing
- Cobiprostone, Non-steroidal anti-inflammatory drug
- Where
- 19 sites in United States
- Volunteers
- 121 people
- Sponsor
- Sucampo Pharma Americas, LLC
Rheumatoid Arthritis
Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.
This study is designed to evaluate the safety, tolerability, PK and PD of multiple subcutaneous injections of GenSci120 in a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase Ib trial involving healthy…
- Trial name
- NCT07040930
- Testing
- GenSci120
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Rheumatoid Arthritis
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
The purpose of this study is to compare the safety and efficacy of multiple doses of PF-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis.
- Trial name
- NCT01393639
- Testing
- PF-04171327, prednisone
- Where
- 93 sites in United States, Bulgaria and 16 more
- Volunteers
- 323 people
- Sponsor
- Pfizer
Arthritis, Traumatic Arthritis
The Medacta International GMK Sphere Post-Marketing Surveillance Study
This is a Post-Marketing Surveillance of GMK Sphere knee prosthesis.
- Conditions
- Arthritis, Traumatic Arthritis, Rheumatoid Arthritis, Poly-arthritis
- Trial name
- NCT02199600
- Testing
- GMK Sphere Knee Replacement
- Where
- 4 sites in Belgium, United Kingdom
- Volunteers
- 500 people
- Sponsor
- Medacta International SA
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with…
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases
- Trial name
- QSIT (NCT07221565)
- Testing
- Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Low-Dose Naltrexone (LDN)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Truway Health, Inc.
Rheumatoid Arthritis, Congenital Hip Dysplasia
A Clinical Trial Study of Hip System in Primary Total Hip Arthroplasty in China
A clinical trial of total Hip system used in Primary Total Hip Arthroplasty in China.
- Conditions
- Rheumatoid Arthritis, Congenital Hip Dysplasia, Avascular Necrosis
- Trial name
- NCT02399007
- Testing
- Total Hip System made in China (SUN, CoCr, Duraloc, Marathon), Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)
- Where
- 8 sites in China
- Volunteers
- 160 people
- Sponsor
- Johnson & Johnson Medical (Suzhou) Ltd.
Rheumatoid Arthritis
Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab)
This non-interventional study will observe the usage and efficacy of RoActemra/Actemra in patients with rheumatoid arthritis (RA) who have recently begun treatment.
- Trial name
- NCT02101307
- Where
- 25 sites in China
- Volunteers
- 400 people
- Sponsor
- Hoffmann-La Roche
Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis
Korean Post-marketing Surveillance for Xeljanz XR
Xeljanz XR extended-release tablets 11 mg (Tofacitinib citrate) is a drug subject to the risk management plan in accordance with Article 4-1-11 of the "Regulation on Safety of Medicinal Products, etc." in Korea.
- Conditions
- Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis
- Trial name
- XRPMS (NCT04876781)
- Testing
- Tofacitinib XR
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers
This study is to test the idea that a controlled release formulation of CE-224,535 may allow for less frequent dosing and exposure to lower levels of drug than an immediate release formulation.
- Trial name
- NCT00782600
- Testing
- suspension IR, CR 1, CR 2
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Arthritis, Rheumatoid
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people.
- Trial name
- NCT07176390
- Testing
- Tulisokibart, Methotrexate
- Where
- 61 sites in United States, Canada and 9 more
- Volunteers
- 185 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis, Myositis
Rheumatoid Arthritis and Myositis Cohort
The primary objective of this research is to establish a well characterized clinical and longitudinal cohort for individuals with Rheumatoid Arthritis (RA) and Myositis to create a place to maintain blood, urine, stool specimens…
- Trial name
- NCT05627089
- Sponsor
- Attune Health Research, Inc.
Rheumatoid Arthritis
Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (DMARDs) approved for…
- Trial name
- NCT00124982
- Testing
- Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy
- Where
- 148 sites in United States, Belgium and 8 more
- Volunteers
- 1,286 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis
This 2 arm study will assess the safety and efficacy of tocilizumab monotherapy versus methotrexate in patients with active rheumatoid arthritis (RA).
- Trial name
- NCT00109408
- Testing
- Methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 147 sites in United States, Argentina and 16 more
- Volunteers
- 673 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects
This study is an open label extension of a previously completed double-blind, randomized study comparing etanercept and methotrexate in subjects with active rheumatoid arthritis.
- Trial name
- NCT00252668
- Testing
- Etanercept, Methotrexate
- Volunteers
- 300 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis
Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis
This is a Phase 1b, randomized, multi-dose, placebo-controlled, dose-escalation, multi-center study of AMP-110 in adult subjects with rheumatoid arthritis.
- Trial name
- NCT02277574
- Testing
- AMP-110
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- MedImmune LLC
Arthritis, Rheumatoid
Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis
To investigate efficacy and safety of 3 doses of BIIL 284 BS in active rheumatoid arthritis (RA) and determine the dose with most positive efficacy / safety ratio. Pharmacokinetic profile will be also obtained.
- Trial name
- NCT02251210
- Testing
- BIIL 284 BS low dose, BIIL 284 BS medium dose, BIIL 284 BS high dose
- Volunteers
- 404 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.